April 20, 2016
The Ministry of Health, Labor and Welfare (MHLW) reiterated its call on physicians to take extra care to the risk of fulminant type 1 diabetes carried by Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) in its drug safety bulletin released on...read more